a2zJanuary 29, 2021 15
Paroxysmal Choreoathetosis Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.
Paroxysmal choreoathetosis is a disorder characterized by movement disorder occurring due to episodes of involuntary movements in limbs, facial and trunk muscles. This disorder being genetic may occur in several members of a genetically connected family or may occur only in a single member of the family. The gene responsible for the disorder was found to be associated with the epilepsy as well.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
January 28, 2021 GMT
CAMBRIDGE, Mass. & OSAKA, Japan (BUSINESS WIRE) Jan 28, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) will be presented as a late-breaking oral session at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) on Friday, January 29 SGT.
Press release content from Newswire. The AP news staff was not involved in its creation.
PatientsLikeMe Partners With Takeda to Empower Patients and Elevate Patient Voice to the Level of Evidence
January 26, 2021 GMT
CAMBRIDGE, Mass. - January 26, 2021 - ( Newswire.com )
The world’s largest integrated community, health management, and real-world data platform PatientsLikeMe announced today it is partnering with Takeda Pharmaceutical Company Limited (“Takeda”). PatientsLikeMe announces a strategic partnership to optimize technology to enhance understanding of the patient experience and improve patients’ ability to partner effectively with their healthcare teams. PatientsLikeMe and Takeda will enhance the digital platform and gather insights on the patient experience and unmet needs, with an initial focus on Rare Diseases, Immunology, Neuroscience/Mental Health and Gastroenterology.
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
Wednesday, January 27, 2021 11:40AM IST (6:10AM GMT)
Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access
Secured Industry-Leading Positions in All Three Technical Areas Evaluated
Shows Strong Performance in Health System Strengthening and Compliance
(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021
Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.